Perioperative Management of Methotrexate and Tofacitinib in Elective Surgery
Direct Recommendation
Continue methotrexate through the perioperative period without interruption, and withhold tofacitinib for at least 3 days before surgery, resuming after adequate wound healing is confirmed.
Methotrexate Management
Continue Through Surgery
Methotrexate should NOT be stopped for elective surgery 1. The highest quality evidence demonstrates that continuing methotrexate is actually safer than discontinuing it:
- A prospective randomized study of 388 patients showed infection/complication rates of only 2% when methotrexate was continued versus 15% when stopped perioperatively 1
- Patients who stopped methotrexate had significantly higher surgical complications (p<0.003) 1
- Disease flares occurred in 8% of patients who stopped methotrexate versus 0% in those who continued 1
Key Anesthetic Considerations for Methotrexate
Avoid nitrous oxide anesthesia completely 2. Nitrous oxide potentiates methotrexate's antifolate effects, increasing risks of:
- Severe stomatitis
- Myelosuppression
- Neurotoxicity
If nitrous oxide was recently used, exercise extreme caution with methotrexate timing 2.
Monitor for drug interactions that increase methotrexate toxicity 2:
- NSAIDs (reduce tubular secretion)
- Penicillins (reduce renal clearance)
- Salicylates, phenytoin, sulfonamides (displace from albumin binding)
Assess renal function carefully - methotrexate is 80-90% renally excreted 2. Impaired renal function dramatically increases toxicity risk.
Tofacitinib Management
Withhold Before Surgery
Stop tofacitinib at least 3 days (72 hours) before elective surgery 3. This recommendation is based on:
- Rapid serum half-life with quick reversal of immunosuppressive effects 3
- Studies showing rapid disease activity increases after stopping, suggesting short-lived immune effects 3
Critical Venous Thromboembolism Risk
Tofacitinib carries significant VTE risk perioperatively 4. In a multi-center study of 53 ulcerative colitis patients:
- 13.2% developed postoperative VTE (7 of 53 patients)
- VTE locations included portomesenteric thrombosis, iliac vein thrombosis, and pulmonary embolism 4
Implement aggressive VTE prophylaxis:
- Extended mechanical prophylaxis
- Consider prolonged pharmacologic prophylaxis beyond standard hospital discharge 4
- Higher vigilance in patients on concurrent corticosteroids (51% in the study were on prednisone) 4
When to Resume Tofacitinib
Resume tofacitinib only after:
- Adequate wound healing is confirmed
- No signs of infection
- Patient is ambulatory with appropriate VTE prophylaxis in place
Consider withholding longer (beyond 3 days) if the patient has:
- History of recurrent infections
- Prior prosthetic joint infection
- Multiple VTE risk factors 3
Specific Anesthetic Technique Considerations
Regional anesthesia: No specific contraindications for methotrexate continuation. For tofacitinib, ensure adequate VTE prophylaxis if neuraxial techniques are used.
General anesthesia: Absolutely avoid nitrous oxide with methotrexate 2. Use volatile anesthetics or total intravenous anesthesia instead.
Monitoring: Check baseline complete blood count and renal function preoperatively in methotrexate patients, as myelosuppression peaks 7-10 days postoperatively 2.
Common Pitfalls to Avoid
- Do NOT routinely stop methotrexate - this outdated practice increases complications 1
- Do NOT use nitrous oxide in any methotrexate patient 2
- Do NOT underestimate tofacitinib VTE risk - extend prophylaxis beyond standard protocols 4
- Do NOT resume tofacitinib too early - wait for confirmed wound healing
- Do NOT forget to assess for concurrent corticosteroid use - this compounds infection and VTE risks
Concurrent Corticosteroid Consideration
Many patients on these DMARDs also take corticosteroids. The evidence shows corticosteroids (particularly prednisone) significantly increase surgical complication risk 1. Maintain current corticosteroid doses perioperatively to avoid adrenal crisis, but recognize this adds to baseline surgical risk.